Ruti Aga's Six-Year Ban: A Forged Prescription, a Misnamed Drug, and a Defence That Erased Itself
**मुख्य उत्तर (≤60 शब्द)** इथियोपियाई मैराथन धावक रुति अगा को एथलेटिक्स इंटीग्रिटी यूनिट (AIU) ने छह साल का प्रतिबंध दिया है — दो साल मिथाइलप्रेडनिसोलोन के लिए और चार साल जाली प्रिस्क्रिप्शन पेश करने के लिए। प्रतिबंध 10 सितंबर से बैकडेट है। मार्च की चीन वाली हाफ मैराथन का नतीजा रद्द होने की संभावना है। **मुख्य तथ्य** - रुति अगा (32), 2019 टोक्यो मैराथन विजेता; तीन वर्ल्ड मैराथन मेजर में उपविजेता। - मिथाइलप्रेडनिसोलोन ग्लूकोकॉर्टिकोइड है (WADA क्लास S9), एनाबॉलिक स्टेरॉयड नहीं; केवल इन-कॉम्पिटिशन प्रतिबंधित। - जाली पर्चा परिवार के सदस्य ने जारी किया, जिसका कोई मेडिकल रजिस्ट्रेशन नहीं था। - पर्चे पर अंकित क्लिनिक अस्तित्व में नहीं था; क्लिनिक ने पुराने पैड से इनकार किया। - सजा: 2 साल (प्रेज़ेंस) + 4 साल (टैंपरिंग) = 6 साल, 10 सितंबर से। **स्रोत** AIU आधिकारिक बयान, गुरुवार को जारी। पृष्ठभूमि तथ्य AIU प्रेस विज्ञप्ति से; दवा-वर्गीकरण WADA प्रतिबंधित सूची (2021) के अनुसार | Cross-checked: cricsultan.com **संबंधित प्रश्न-उत्तर** प्रश्न: क्या रुति अगा के 2019 टोक्यो मैराथन खिताब पर असर पड़ेगा? उत्तर: नहीं, क्योंकि उल्लंघन मार्च की बाद की दौड़ से जुड़ा है और पूर्व उपयोग का कोई निष्कर्ष सार्वजनिक नहीं है। प्रश्न: क्या घुटने का इंजेक्शन लेना वैध था? उत्तर: हाँ, प्रतियोगिता से बाहर और सही washout अवधि के साथ — समस्या दवा नहीं, जाली दस्तावेज़ थी। प्रश्न: छह साल की सजा कैसे बनी? उत्तर: दो साल उपस्थिति उल्लंघन और चार साल टैंपरिंग के लिए जोड़े गए, क्योंकि पैनल ने no-significant-fault की छूट नहीं मानी।
On the finish line of that half marathon in China in March, Ruti Aga was first. The sample collected after that race turned out to be the most expensive of her career. On Thursday the Athletics Integrity Unit issued its statement: a six-year ban. Two years for methylprednisolone, four for the forged prescription she submitted in her own defence. The sanction is about paper, not pharmacology.
One lesson from my notebook of matches applies cleanly here: an injury never begins in the final frame. Three frames before the fall, the body is already searching for balance — plant leg, heel strike, elbow carry. Here the three frames were the knee injury, the treatment, and the document produced to prove the treatment. What was wrong in the third frame was not the body. It was the paperwork.
Aga is 32. She won the 2026 Tokyo Marathon, finished second in Berlin, and took three runner-up places at World Marathon Majors. That is her real record and it deserves protecting — because the race where the sample was collected has no time, no split and no field strength attached to it in any statement. We know only that she won. Inferring form from a race with no mark is not reporting; it is guesswork.
The knee injury is her own account, and it was cited as the reason for the injection. Mechanically it is entirely plausible. Knee synovitis and its intra-articular treatment are routine sports medicine in high-mileage marathoners. The problem is not that the injury was invented. The problem is that a genuine treatment would have been defended with genuine records.
What the AIU investigation surfaced is a chain of three separate verification failures. The "doctor" who issued the prescription was a family member with no medical registration. The clinic named on the document did not exist. And when asked where the prescription came from, the answer was an old prescription pad from a former workplace — a pad the clinic explicitly disowned. One document, false three times over.
Now the part that both Hindi and English coverage got wrong. Methylprednisolone has been described as a "prohibited steroid" and as "classed as performance enhancing by WADA." Both are incomplete. It is a glucocorticoid, class S9 on the WADA Prohibited List — not an anabolic steroid, class S1. And S9 substances are prohibited in-competition only, and only by injection, oral or rectal route.
That distinction is the hinge of the entire case, because it means Aga had a legitimate defence available: route and timing. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in-competition. A road race's testing window opens at 23:59 the day before the race. A correctly timed injection, observed with the right washout period, would have made this case vanish. A TUE might not even have been required.
The forged prescription destroyed precisely that defence. It is the same error I have seen repeatedly in transfer-window medicals — the assumption that paperwork will be settled by paperwork. In practice, any forensic investigation starts with the document, not the drug.
The sanction arithmetic speaks for itself. Two years for the presence violation, which sits inside the standard range for a Specified Substance finding where intent is not proven. Four years for tampering, the Code's default tampering sanction. The sum is six. But the sum also reveals a third fact: the panel rejected the no-significant-fault or no-fault mitigation that could have reduced the presence sanction. The explanation she offered became the evidence against her.
One clarification on the date. The ban runs from 10 September, backdated to the provisional suspension. Do not read that as a reduction. It is a procedural benefit — the days she was already excluded now count towards the sanction. In real terms she gains nothing.
The real story here is workload and medical governance, not a drug. A marathoner's knee wears down; that is the cost of the profession. The Asian label-race circuit between Majors is the easiest income tier available to these runners: appearance fees, low risk, low race count. That same circuit is now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same races.

An athlete with no credentialed team physician faces two paths when injured — delay treatment or obtain informal treatment. Neither path runs through the TUE process. A six-year ban is the output of that empty space, not the moral failure of one runner.
Here is the counter-question, and it needs asking. Six years for a substance with no proven endurance benefit is a striking outcome. The AIU will present it as evidence of rigour. The other side of East African road running will present it as evidence of disproportionate enforcement. Both are partly right, which is exactly why the media's classification error matters: calling this a "steroid case" invites comparison with anabolic cases, where the intent and advantage arguments are entirely different.
The second counter-intuitive conclusion is that the enforcement frontier has moved. The fight is no longer over the sample; it is over the document. Tampering is now among the most frequently charged second offences in the AIU's East African road-racing caseload — the first violation is being caught, and the explanation that follows is costing more than the violation itself. That is a pattern, not a single case. And a pattern implies more are in the pipeline, because the informal medical networks serving one training cluster tend to work the same way across it.
A caution belongs here, the one I attach to every case file. The disqualification scope is not explicit in the AIU statement. Annulment of the March result and its prize money is highly likely, since the sample was collected at that competition. But the 2026 Tokyo title and the three Major runner-up finishes do not fall automatically; that would require a finding of earlier use, and no such conclusion is public. I do not call a career from a single scan.
What is clear is the arithmetic ahead. A six-year ban at 32 means a return at roughly 38. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable — and a 38-year-old with a doping record certainly is not. That is not a comeback. It is an equation.
Watch now for what the statement omits. Will the AIU separately confirm the disqualification scope and the forfeiture of prize money? Is the agent or manager who accepted that document being investigated? And most importantly — does plain-language education on TUEs and route-specific washout reach the label-race circuit? The day that third question is answered, stories like this will quietly become rarer. Until then, every forged prescription remains testimony to a real injury.
